U.S. IPO Weekly Recap: Healthcare Software program Leads $1.3B IPO Week; Novelis Calls Off IPO

5 IPOs debuted this week and raised over $1.3 billion in proceeds. One SPAC additionally listed. One identify that didn’t be part of the fray was aluminum firm Novelis (NVL), which known as off its deliberate $878 million IPO at the eleventh hour. Three IPOs and 4 SPACs submitted preliminary filings this previous week.

Hospital billing platform Waystar (WAY) priced on the midpoint to boost $968 million at a $3.7 billion market cap. Waystar supplies cloud funds software program funds for healthcare suppliers. The corporate at the moment serves roughly 30,000 purchasers, representing roughly a million distinct suppliers training throughout quite a lot of care websites. In 2023, Waystar facilitated over 5 billion healthcare funds transactions, together with over $1.2 trillion in gross claims quantity, spanning roughly 50% of sufferers within the US. The corporate is working in a big market and instructions a 109% dollar-based web retention fee, however is extremely leveraged. IT completed down 4%.

Location-sharing cellular app Life360 (LIF) raised $155 million at a $2.3 billion market cap in its Nasdaq uplisting. The corporate’s core providing is the Life360 cellular app, which incorporates options like communications, driving security, digital security, and site sharing, and operates beneath a “freemium” mannequin. Its suite of product and repair choices are system and platform-agnostic. As of March 31, 2024, there have been roughly 66.4 million MAUs and 1.9 million international paying teams, or “circles,” on the Life360 Platform. The corporate can be listed on the Australian Securities Trade. Life360 completed up 1%.

CNS dysfunction biotech Rapport Therapeutics (RAPP) priced on the midpoint to boost $136 million at a $633 million market cap. Its most superior candidate has accomplished Part 1 trials in wholesome adults and is anticipated to enter a Part 2a proof-of-concept trial in drug-resistant focal epilepsy in mid-2024, with topline outcomes anticipated in mid-2025. The corporate believes the candidate additionally has therapeutic potential in peripheral neuropathic ache and bipolar dysfunction. IT completed up 22%.

Israeli glass movie producer Gauzy (GAUZ) priced its upsized IPO on the low finish to boost $75 million at a $341 million market cap. Gauzy supplies quite a lot of PDLC and SPD movies that are laminated or retrofitted onto glass. The movies can dim gentle, or present clear shows. Main finish markets for Gauzy embody the automotive, aerospace, and development sectors. The corporate grew its income 59% in 2023 however stays unprofitable with a money move loss. Gauzy completed down 7%.

Electrical bike retailer Fly-E Group (FLYE) priced its downsized IPO on the low finish to boost $9 million at a $97 million market cap. IT sells its bike, e-bike, and e-scooter merchandise on-line and thru retailers within the US and Canada. The corporate is worthwhile, and rising quick, however competes with bigger and extra established gamers. Fly-E Group completed flat.

Clean examine Chenghe Acquisition II (CHEB.U) raised $75 million to focus on companies in, or with a concentrate on, Asian markets.

6 IPOs During the Week of June 3rd, 2024
Issuer Enterprise	Deal Measurement	Market Cap at IPO	Value vs. Midpoint	First Day Return	Return at 06/07
Rapport Therapeutics (RAPP)	$136M	$633M	0%	+22%	+22%
Part 2-ready biotech growing small molecule therapies for CNS issues.
Life360 (LIF)	$155M	$2,304M	0%	+0%	+1%
Offers a location sharing cellular app focused to households.
Chenghe Acquisition II (CHEB.U)	$75M	$103M	0%	+0%	+0%
Clean examine firm focusing on companies in or with a concentrate on Asian markets.
Fly-E Group (FLYE)	$9M	$97M	-11%	+20%	+0%
Makes and sells electrical bikes, bikes, and scooters.
Waystar (WAY)	$968M	$3,698M	0%	-4%	-4%
Offers cloud-based income administration software program for the healthcare trade.
Gauzy (GAUZ)	$75M	$341M	-6%	-3%	-7%
Israel-based producer of good glass movies.

Click on to enlarge

Three IPOs submitted preliminary filings this previous week. Part 3-ready irritation biotech Alumis (ALMS) filed to boost $100 million. Breathe BioMedical (BRTH), a Canadian developer of a diagnostics system for breast most cancers, filed to boost $12 million. China-based parking gear supplier UEOPLE Technology (UEOP) filed to boost $9 million.

4 SPACs additionally submitted preliminary filings this previous week. EQV Group-backed EQV Ventures Acquisition (EQVU) filed to boost $350 million to focus on the vitality sector. GigCapital7 (GIGGU), led by semiconductor veteran Avi Katz, filed to boost $250 million. M3-Brigade Acquisition V (MBAV.U), led by turnaround veteran Mohsin Meghji, filed to boost $250 million to focus on vitality in North America. Rising Dragon Acquisition (RDACU) filed to boost $50 million to focus on small-cap companies.

7 Filings During the Week of June 3rd, 2024
Issuer Enterprise	Deal Measurement	Sector	Lead Underwriter
Alumis (ALMS)	$100M	Health Care	Morgan Stanley
Part 3-ready biotech growing kinase inhibitors for immune-mediated ailments.
Breathe BioMedical (BRTH)	$12M	Health Care	Maxim
Canadian medical Technology firm growing a breath check for breast most cancers.
EQV Ventures Acquisition (EQVU)	$350M	SPAC	BTIG
Clean examine firm backed by EQV Group focusing on the vitality sector.
GigCapital7 (GIGGU)	$250M	SPAC	Spartan Capital
Clean examine firm led by semiconductor veteran Avi Katz.
Rising Dragon Acquisition (RDACU)	$50M	SPAC	Lucid Capital Markets
Clean examine firm focusing on small-cap companies.
UEOPLE Technology (UEOP)	$9M	Technology	Tiger Brokers
Offers clever parking gear and associated merchandise in China.
M3-Brigade Acquisition V (MBAV.U)	$250M	SPAC	Cantor Fitz.
Clean examine firm led by turnaround veteran Mohsin Meghji focusing on vitality in North America.

Click on to enlarge

Two sizable IPOs are scheduled for the week forward.

Precision drugs firm Tempus AI (TEM) plans to boost $400 million at a $6.2 billion market cap. The corporate supplies its Tempus Platform, which incorporates proprietary software program and information pipelines to allow improvement of extra personalised therapies. Extremely unprofitable however rising, Tempus’ choices have been utilized by roughly 95% of the most important public prescribed drugs, and its medical next-generation sequencing quantity in oncology rose nine-fold from 2018 to 2023.

Australia-listed biotech Telix Prescription drugs (TLX) plans to boost $202 million at a $4.2 billion market cap. Telix is targeted on the event and commercialization of therapeutic and diagnostic radiopharmaceuticals, with a pipeline of candidates throughout varied oncology indications. Its lead product, Illuccix, is a commercially accessible imaging agent for prostate most cancers that has generated about $550 million in gross sales since its business launch in April 2022.

U.S. IPO Calendar
Issuer Enterprise	Deal Measurement Market Cap	Value Vary Shares Filed	High Bookrunners
Telix Pharmaceuticals (TLX) North Melbourne, Australia	$202M $4,237M	$11.87 17,000,000	Jefferies Morgan Stanley
Industrial-stage Australian biotech growing therapeutic and diagnostic radiopharmaceuticals.
Tempus AI (TEM) Chicago, IL	$400M $6,204M	$35 – $37 11,100,000	Morgan Stanley JPMorgan
Offers information and analytics instruments for precision drugs.

Click on to enlarge

Road analysis is anticipated for 4 firms within the week forward, and one lock-up interval will likely be expiring.

IPO Market Snapshot

The Renaissance IPO Indices are market cap-weighted baskets of newly public firms. As of 6/6/2024, the Renaissance IPO Index was up 6.5% year-to-date, whereas the S&P 500 was up 12.9%. Renaissance Capital’s IPO ETF (IPO) tracks the index, and prime ETF holdings embody Kenvue (KVUE) and Nu Holdings (NU). The Renaissance Worldwide IPO Index was down 0.8% year-to-date, whereas the ACWX was up 7.6%. Renaissance Capital’s Worldwide IPO ETF (IPOS) tracks the index, and prime ETF holdings embody Sensible and Porsche.

Original Post

Editor’s Observe: The abstract bullets for this text had been chosen by In search of Alpha editors.